Skip to main content

Danaher Corporation stock price and financials

  • DHR · NYSE
  • Instruments
  • Life Sciences Tools & Services
  • S&P 500
$233.02+0.37%Close 13 Nov 2026
Market value
$163.0B
P/E
37.64
EV / EBITDA
23.70
Dividend yield
0.6%
Beta · 1 year
0.53
Return · 1 year
+6.2%
52-week range$160.93 — $242.80

Share price close 16 Nov 2026

+0.2%1 monthHigh $236.98Low $224.24
$220$225$230$235$240Q3 FY2026 report filed 21 Oct 202623 Oct29 Oct4 Nov10 Nov16 Nov
+43.3%6 monthsHigh $236.98Low $163.86
$160$180$200$220$240Q2 FY2026 report filed 21 Jul 2026Q3 FY2026 report filed 21 Oct 20264 Jun2 Jul30 Jul26 Aug23 Sep20 Oct16 Nov
+1.3%year to dateHigh $242.05Low $161.91
$150$175$200$225$250Q4 FY2025 report filed 24 Feb 2026Q1 FY2026 report filed 21 Apr 2026Q2 FY2026 report filed 21 Jul 2026Q3 FY2026 report filed 21 Oct 202611 Feb30 Mar14 May1 Jul17 Aug1 Oct16 Nov
+4.9%1 yearHigh $242.05Low $161.91
$150$175$200$225$250Q4 FY2025 report filed 24 Feb 2026Q1 FY2026 report filed 21 Apr 2026Q2 FY2026 report filed 21 Jul 2026Q3 FY2026 report filed 21 Oct 2026Jan 26Mar 26Apr 26Jun 26Aug 26Sep 26Nov 26
+11.4%3 yearsHigh $280.76Low $161.91
$150$200$250$300Q4 FY2023 report filed 21 Feb 2024Q1 FY2024 report filed 23 Apr 2024Q2 FY2024 report filed 23 Jul 2024Q3 FY2024 report filed 22 Oct 2024Q4 FY2024 report filed 20 Feb 2025Q1 FY2025 report filed 22 Apr 2025Q2 FY2025 report filed 22 Jul 2025Q3 FY2025 report filed 21 Oct 2025Q4 FY2025 report filed 24 Feb 2026Q1 FY2026 report filed 21 Apr 2026Q2 FY2026 report filed 21 Jul 2026Q3 FY2026 report filed 21 Oct 2026Apr 24Sep 24Feb 25Aug 25Jan 26Jun 26Nov 26
+231%10 yearsHigh $294.71Low $68.55
$0$100$200$300Apr 18Sep 19Feb 21Jul 22Jan 24Jun 25Nov 26

Quarterly or annual report filed

In one paragraph

Danaher Corporation reported revenue of $24.6 billion for fiscal year 2025 (the twelve months to 31 Dec 2025), up 2.9% from fiscal 2024. Net income was $3.61 billion and diluted earnings per share $5.05.

In its latest reported quarter, the third quarter of fiscal 2026 (the three months to 25 Sep 2026), revenue was $6.55 billion, up 8.3% from a year earlier.

Figures from Danaher Corporation's annual and quarterly reports, compiled and checked by AapWire. Latest report filed 21 Oct 2026.

Against Health Care

Growth
Bottom quarter
Revenue +2.0% a year over five years · 34th of 37
Profitability
Lower half
Return on invested capital 6.8%, five-year average · 28th of 38
Balance sheet
Lower half
Net debt 2.8× EBITDA · 27th of 38
Valuation
Above the median
P/E 37.6 · 23rd of 36

Among the sector's S&P 500 members with the figure; the longer the bar, the better placed. Debt and P/E rank lower first.

Revenue FY2025
$24.57B+2.9%
Net income
$3.61B−7.3%
Diluted EPS
$5.05−4.5%
Gross margin
59.1%−0.4 pts
Free cash flow
$5.26B−0.7%
Net debt
$15.10B+0.2%

Fiscal 2025 against fiscal 2024; bars show the last 10 fiscal years; net debt is borrowings and operating lease liabilities less cash and short-term investments at the year end.

Revenue and net income fiscal 2016–2025

  • Revenue
  • Net income
$0$10B$20B$30BRevenue, FY16: $16.88BNet income, FY16: $2.55BFY16Revenue, FY17: $18.33BNet income, FY17: $2.49BFY17Revenue, FY18: $19.89BNet income, FY18: $2.65BFY18Revenue, FY19: $17.91BNet income, FY19: $3.01BFY19Revenue, FY20: $22.28BNet income, FY20: $3.65BFY20Revenue, FY21: $24.8BNet income, FY21: $6.43BFY21Revenue, FY22: $26.64BNet income, FY22: $7.21BFY22Revenue, FY23: $23.89BNet income, FY23: $4.76BFY23Revenue, FY24: $23.88BNet income, FY24: $3.9BFY24Revenue, FY25: $24.57BNet income, FY25: $3.61BFY25

Latest quarter · Q3 FY2026 to 25 Sep 2026, filed 21 Oct 2026 · Full results →

Revenue
$6.55B+8.3% on a year
Gross margin
58.5%+0.3 pts on a year
Operating income
$1.25B+7.9% on a year
Net income
$1.24B+36.0% on a year
Diluted EPS
$1.75+37.8% on a year
Free cash flow
$1.63B+19.1% on a year

Comparable companies All of Health Care →

Danaher Corporation beside the other S&P 500 members in Life Sciences Tools & Services, by market value.

Danaher Corporation and comparable companies
CompanyMarket valueDay1 yearRevenue growthNet marginP/E
Danaher CorporationDHR$163.0B+0.4%+6.2%+5.5%16.9%37.6
Agilent TechnologiesA$48.72B+0.5%+14.8%+8.6%19.5%33.8
IQVIAIQV$43.52B−2.2%+20.0%+8.8%8.1%31.2
IlluminaILMN$30.43B−4.2%+65.3%+5.8%19.7%34.0
Charles River LaboratoriesCRL$16.06B−0.8%+97.1%−1.2%1.0%399.6
Bio-TechneTECH—−0.1%+18.6%———
Mettler ToledoMTD—+0.5%+20.1%———

Market value and moves at the latest close. Revenue growth compares the last twelve months with the twelve before; net margin and P/E over the last twelve months; P/E is left blank where earnings are negative.

Margins fiscal 2016–2025

  • Gross
  • Operating
  • Net
0%25%50%75%59.1%19.1%14.7%FY16FY19FY22FY25

Danaher Corporation revenue by segment, product and region

Fiscal years, as the company cuts its revenue in its annual reports; the change on a year under each figure. A change is left out from a loss, from a sliver of revenue, or across a change in how the company reports.

By segment

Danaher Corporation revenue by segment, by fiscal year
RevenueFY 2021FY 2022FY 2023FY 2024FY 2025
Diagnostics$9.84B$10.85B+10.2%$9.58B−11.7%$9.79B+2.2%$9.94B+1.6%
Life Sciences$6.39B$7.04B+10.1%$7.14B+1.5%$7.33B+2.6%$7.33B+0.1%
Biotechnology$8.57B$8.76B+2.2%$7.17B−18.1%$6.76B−5.8%$7.29B+7.9%
Total revenue$24.80B$26.64B$23.89B$23.88B$24.57B

By product

Danaher Corporation revenue by product, by fiscal year
RevenueFY 2021FY 2022FY 2023FY 2024FY 2025
Recurring revenue$19.14B$20.88B+9.1%$18.68B−10.5%$19.37B+3.7%$20.13B+3.9%
Nonrecurring revenue$5.67B$5.77B+1.8%$5.21B−9.7%$4.51B−13.4%$4.44B−1.5%
Total revenue$24.80B$26.64B$23.89B$23.88B$24.57B

By region

Danaher Corporation revenue by region, by fiscal year
RevenueFY 2021FY 2022FY 2023FY 2024FY 2025
North America$9.80B$11.73B+19.7%$9.96B−15.1%$10.29B+3.4%$10.36B+0.6%
High-growth markets$7.77B$7.71B−0.8%$7.19B−6.7%$6.87B−4.5%$7.02B+2.2%
Western Europe$5.88B$5.86B−0.3%$5.47B−6.7%$5.46B−0.2%$5.94B+8.8%
Other developed markets$1.36B$1.34B−0.9%$1.27B−5.6%$1.25B−1.3%$1.25B−0.1%
Total revenue$24.80B$26.64B$23.89B$23.88B$24.57B

Financial statements

Fiscal years, the latest ending 31 Dec 2025. Amounts in USD. On a narrow screen the table opens on the latest year and scrolls back.

Income statement

Danaher Corporation income statement, annual
PeriodFY 2016FY 2017FY 2018FY 2019FY 2020FY 2021FY 2022FY 2023FY 2024FY 2025
Revenue$16.88B$18.33B$19.89B$17.91B$22.28B$24.80B$26.64B$23.89B$23.88B$24.57B
Revenue growth+17.0%+8.6%+8.5%−10.0%+24.4%+11.3%+7.4%−10.3%−0.1%+2.9%
Gross profit$9.33B$8.57B$9.51B$9.98B$12.47B$15.24B$16.19B$14.03B$14.21B$14.52B
Operating income$2.74B$2.57B$3.06B$3.27B$4.23B$6.38B$7.54B$5.20B$4.86B$4.69B
Net income$2.55B$2.49B$2.65B$3.01B$3.65B$6.43B$7.21B$4.76B$3.90B$3.61B
Diluted EPS$3.65$3.53$3.74$4.05$4.89$8.61$9.66$6.38$5.29$5.05
Gross margin55.3%46.8%47.8%55.7%56.0%61.4%60.8%58.7%59.5%59.1%
Operating margin16.2%14.0%15.4%18.3%19.0%25.7%28.3%21.8%20.4%19.1%
Net margin15.1%13.6%13.3%16.8%16.4%25.9%27.1%19.9%16.3%14.7%

Cash flow

Danaher Corporation cash flow, annual
PeriodFY 2016FY 2017FY 2018FY 2019FY 2020FY 2021FY 2022FY 2023FY 2024FY 2025
Operating cash flow$3.52B$3.48B$4.02B$3.95B$6.21B$8.36B$8.52B$7.16B$6.69B$6.42B
Capital expenditure$589.6M$570.7M$584.0M$636.0M$791.0M$1.24B$1.12B$1.38B$1.39B$1.16B
Free cash flow$2.93B$2.91B$3.44B$3.32B$5.42B$7.12B$7.40B$5.78B$5.30B$5.26B

Balance sheet and shares

Danaher Corporation balance sheet and shares, annual
PeriodFY 2016FY 2017FY 2018FY 2019FY 2020FY 2021FY 2022FY 2023FY 2024FY 2025
Cash and equivalents$963.7M$630.3M$787.8M$19.91B$6.04B$2.59B$6.00B$5.86B$2.08B$4.62B
Total debt$12.27B$10.52B$9.74B$22.53B$22.18B$23.27B$20.62B$19.54B$17.15B$19.72B
Shareholders' equity$23.00B$26.36B$28.21B$30.27B$39.77B$45.17B$50.08B$53.49B$49.54B$52.53B
Diluted shares700M706M710M726M719M737M737M743M737M716M

Quarterly figures

The last eight fiscal quarters, the latest ending 25 Sep 2026. Year-on-year growth compares the same quarter of the previous fiscal year.

Danaher Corporation quarterly financial figures
PeriodQ4 FY2024Q1 FY2025Q2 FY2025Q3 FY2025Q4 FY2025Q1 FY2026Q2 FY2026Q3 FY2026
Revenue$6.54B$5.74B$5.94B$6.05B$6.84B$5.95B$6.26B$6.55B
Revenue, year on year+2.1%−0.9%+3.4%+4.4%+4.6%+3.7%+5.5%+8.3%
Gross margin59.5%61.2%59.3%58.2%58.0%60.3%57.6%58.5%
Operating income$1.43B$1.27B$760.0M$1.15B$1.50B$1.34B$1.13B$1.25B
Net income$1.09B$954.0M$555.0M$908.0M$1.20B$1.03B$870.0M$1.24B
Diluted EPS$1.49$1.32$0.77$1.27$1.68$1.45$1.23$1.75
Free cash flow$1.50B$1.05B$1.09B$1.37B$1.75B$1.08B$1.26B$1.63B

Operating KPIs

The operating figures Danaher Corporation reports beside its statements, then its revenue by product, segment and region, latest period first. Each links to its full history.

Danaher Corporation operating KPIs
KPILatestPeriodChange on a yearRecent periods
Recurring revenue$5.4Bquarter to 25 Sep 2026up 7.6%
Nonrecurring revenue$1.2Bquarter to 25 Sep 2026up 11.5%
Diagnostics revenue$2.9Bquarter to 25 Sep 2026up 17.0%
Life Sciences revenue$1.9Bquarter to 25 Sep 2026up 4.1%
Biotechnology revenue$1.8Bquarter to 25 Sep 2026up 0.5%
North America revenue$2.7Bquarter to 25 Sep 2026up 6.2%
High-growth markets revenue$2.0Bquarter to 25 Sep 2026up 15.0%
Western Europe revenue$1.5Bquarter to 25 Sep 2026up 6.7%

Method

Each period is read from the report the company filed and checked against accounting identities before it is shown; a figure that does not pass is left blank rather than estimated. Free cash flow is operating cash flow less capital expenditure. Fiscal years follow the company's own calendar. See data and methodology.

The same figures as plain text and JSON.

Questions

What was Danaher Corporation's revenue in fiscal 2025?

$24.6 billion for fiscal year 2025 (the twelve months to 31 Dec 2025), as reported in its annual report.

What was Danaher Corporation's net income in fiscal 2025?

$3.61 billion for fiscal year 2025 (the twelve months to 31 Dec 2025).

What were Danaher Corporation's diluted earnings per share in fiscal 2025?

$5.05 for fiscal year 2025 (the twelve months to 31 Dec 2025).

What is Danaher Corporation's gross margin?

59.1% for fiscal year 2025 (the twelve months to 31 Dec 2025): gross profit divided by revenue.

What is Danaher Corporation's operating margin?

19.1% for fiscal year 2025 (the twelve months to 31 Dec 2025): operating income divided by revenue.

How much free cash flow did Danaher Corporation generate in fiscal 2025?

$5.26 billion for fiscal year 2025 (the twelve months to 31 Dec 2025): operating cash flow less capital expenditure.

Where does Danaher Corporation's revenue come from?

In fiscal 2025, by segment: Diagnostics $9.94B (40%), Life Sciences $7.33B (30%), Biotechnology $7.29B (30%), out of $24.57B in all, as stated in its annual report.

In the terminal

Twenty years of Danaher Corporation's figures, KPIs, guidance and a cash-flow valuation.

  • Every report line and operating figure, quarter by quarter
  • Guidance against what was delivered
  • Insider trades and institutional holders
  • Alerts on results, filings and price
See plans